Daniel Nathan

Instructor and K12 Scholar @TischCancer @IcahnMountSinai interested in clonal hematopoiesis and myeloid malignancies

[Daniel Nathan @DNathanMD]

Should we be screening IBD patients for CHIP? Proud of this multi-disciplinary collaboration describing the risk for CHIP in IBD. Thanks to @ZeynepHG @EsaiMyvizhi @bkmarcellino and many others @TischCancer @IcahnMountSinai @mountsinaiIBD https://t.co/8nXk2f1wew

[Dr. Zeynep Hülya Gümüş 🕊️ @ZeynepHG]

We just published ! Clonal hematopoiesis of indeterminate potential in Crohn's Disease and Ulcerative Colitis. Great work by first authors
@EsaiMyvizhi and @DNathanMD from @SinaiGenetics @TischCancer @IcahnMountSinai @mountsinaiIBD https://t.co/PSFkBhjAN3

[Pradeep Natarajan @pnatarajanmd]

In a cross-sectional study, investigators describe distinct patterns of myeloid and lymphoid clonal hematopoiesis by inflammatory bowel disease type, age, and treatment vs controls https://t.co/0SKdKl5fnf @medrxivpreprint

[Daniel Nathan @DNathanMD]

Thrilled that our commentary on @NCCN guidelines for interpreting TP53 variants in the context of CHIP versus mosaic LFS is finally out! Many thanks to our wonderful collaborators and reviewers @TischCancer @JCOPO_ASCO https://t.co/IeKMLMQaDd

[Nancy Gillis 🆖☮️ @nancykgillis]

Such an important reference for those doing #CHIP research from a true leader in the field @KellyLBolton Thanks for sharing your knowledge. 💡

How low can you go?: Methodologic considerations in clonal hematopoies... https://t.co/v9SvN0dfIs

[David Steensma, MD @DavidSteensma]

Our proteomics analysis of the large CANTOS CV trial is now online @BloodAdvances led by Janghee Woo (now @WinshipAtEmory). Clonal hematopoiesis was associated with incident anemia & markers of inflammation which were attenuated by IL-1b inhibitor therapy. https://t.co/Zqxnf8SHy9

[Alex Bick @AlexBickMDPhD]

Conceptually flawed paper from deCODE on #CH in @NatureGenet today
TLDR: Different clones have distinct disease profiles so lumping distinct forms of CH together is uninformative. #CHIP is associated with CVD in both smokers and non-smokers in full UKB 🧵https://t.co/0QnqPs1nlE

[Daniel Nathan @DNathanMD]

Congratulations @JonAnker1! So proud of our amazing fellows @SinaiHemeOnc

[Mount Sinai Tisch Cancer Center @TischCancer]

Congratulations to @JonAnker1 on receiving a Young Investigator Award from @sitcancer. He is presenting at #SITC23.
@MattGalsky @IcahnMountSinai @BhardwajLab

[Daniel Nathan @DNathanMD]

Excited to share our review of CH and inflammation covering clinical applications, pre-clinical mechanisms, and next steps in the field. Thanks to co-authors at @SinaiHemeOnc and @TischCancer. Online now @CHematology.
https://t.co/rGixL5np98

[Mrinal Patnaik @MrinalPatnaik]

Germline DDX41 mutant predisposition syndromes: Slow driver states to hematological malignancies. https://t.co/qEEEc0OZEA Unanswered questions and future directions @tchlon #DDX41 #Myeloid #Germlinepredisposition @AjHematology @MayoCancerCare @MayoClinicCIM

[Caitlyn Vlasschaert @DrFlashHeart]

Our report on CHIP and infection risk in the UK Biobank is out now @LeukemiaJnl.

https://t.co/Sy7O2vnEgd

We illustrate the importance of accounting for incident myeloid cancer development in observational studies of CHIP, particularly when the observation period is very long.

[Pradeep Natarajan @pnatarajanmd]

Enrichment of TET2 clonal hematopoiesis among individuals w HFpEF v controls & adverse prognosis among those w TET2 CH + HFpEF. Murine model recapitulates HFpEF exacerbation in Tet2-deficient v WT bone marrow https://t.co/5f4PON7ALy @CircAHA
[1/2]

[Pradeep Natarajan @pnatarajanmd]

Current studies examining putative risk factors of CHIP are cross-sectional.
Led by @M_Mesbah_Uddin @smsaadatagah &w @CBallantyneMD, we use longitudinal exome seq of 4,187 over 21y to better prioritize clinical & genetic risk factors for incident CHIP. https://t.co/0puTrtjglV

[Philipp Rauch @PhilRauchMD]

Happy to share our work identifying common pathways promoting heightened innate immune cell activation with loss of either Dnmt3a or Tet2, the two most commonly mutated genes in CHIP, in the context of atherosclerosis.
https://t.co/wrO5yxyMBO

[Daniel Nathan @DNathanMD]

@Lachelle_Dawn Completely agree and beyond that, need to ensure reclassified actual pathogenic VUS are appropriately followed up. A lot to stay on top of, and not helped by subclinical noise!

[Daniel Nathan @DNathanMD]

Excited to share our commentary on novel work by Ramanathan and colleagues demonstrating how cigarette smoke can affect clonal dynamics https://t.co/6UJ9KYr5Xu

[Frontiers - Oncology @FrontOncology]

New research: Cigarette smoke stimulates clonal expansion of Jak2V617F and Tet2-/- cells: Introduction

Somatic mutations in myeloid growth factor pathway genes, such as JAK2, and genes involved in epigenetic regulation, such as TET2, in… #oncology https://t.co/1xsvsRLR5M

[Anand Patel @Anand_88_Patel]

Another excellent MPN-AP/BP review (by @arampotas @donalmclor et al) - much needs to be done for our patients with with disease! #mpnsm #leusm

https://t.co/Yh5njaFtYc

[Sanam Loghavi, MD صنم لغوی 🔬🧬 @sanamloghavi]

https://t.co/6AMetMgBAG
#hemepath #Pathtwitter #PathX

@KMirza @cullen_lilley

[Daniel Nathan @DNathanMD]

A great population-level look into risks of AML and MDS in DDX41 germline and somatic variants. Low rates of CH in germline but an elevated MCV may portend evolution! https://t.co/0rrbHR16vw